Charles is currently in charge of Intralink’s life science and med-tech projects in Japan. His background is in biological and chemical engineering, completing undergrad, masters and Ph.D. training at Nagoya University in Japan. Prior to joining Intralink, he worked with a global pharma in 2007-2008 on a digital transformation and compliance related project and contributed to setting up its spin out.

He has direct industry experience in contract research services (ADME-PK/Tox, CRISPR-Cas9 screening), drug licensing (therapeutic DNA cancer vaccines, “licensed generics”, bio-betters, cellular therapies), gene therapy, novel vaccine DDS, IVD kits (myeloma diagnosis and monitoring, hormone, novel colon cancer early detection), IVD devices, components and consumables (liquid biopsy, sample prep), custom IVD reagent/kit development (recombinant antibodies, including SARS-CoV-2 antibodies and PCR kits), strategic LP investor search, precision oncology (RWD platform, IO/WES services and biomarker discovery platform, MTB support NGS interpretation software), digital health (e-Patient platform development), digital wellness (stress mitigation and dementia/fall prevention apps, early cancer detection wearable), NGS (single cell, long-read), and protein engineering/synthetic biology for materials/API production.

He is trilingual and has been living in Japan since the year 2000.

Since joining Intralink China in 2017, Olex has focused on medtech and pharma initiatives and has supported more than a dozen UK, European and North American IVD, biotech and pharma clients, delivering opportunity assessments and developing and implementing market entry strategies. His recent initiatives include bringing a

US diagnostic-grade single-cell sequencing tech developer Mission Bio into the Chinese market and establishing channels sales for a German biomaterials company Biotechrabbit. Olex is a certified sinologist and a business degree holder from Shanghai University of Finance and Economics. He has more than 14 years of working experience in China.

Ruslan is a medtech/digital health specialist at Intralink – an international business development consultancy with a deep specialism in East Asia. At Intralink, he mainly focuses on the life sciences and med-tech sectors and has helped dozens of clients in digital healthcare, genomics, precision medicine as well as advanced medical technologies to enter the Korean market. Specifically, he has brought several companies such as Oxford Nanopore Technologies, Mission Bio and Random42 to the Korean market and recently licensed Syapse’s precision medicine platform to one of the top Korean hospitals. He has also been invited by the UK’s Department for International Trade to present on South Korean digital health opportunities in London, Manchester, and Cardiff and provides an annual webinar on the Koreanlife science opportunities for the global bank, Santander.